Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.32 |
| ▸ | APP | P05067 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305608 | 1.00 | TBXAS1 (0.35) | TBXAS1IDO1AGXTAPLNRFFAR1 | |
| SCHEMBL14980745 | 0.84 | IDO1 (0.40) | TBXAS1IDO1AGXTAPLNRFFAR1 | |
| SCHEMBL23648276 | 0.82 | IDO1 (0.38) | TBXAS1IDO1AGXTAPLNRAPP | |
| SCHEMBL23648273 | 0.81 | IDO1 (0.36) | TBXAS1IDO1AGXTAPLNRAPP | |
| SCHEMBL10100258 | 0.77 | MEN1 (0.37) | TBXAS1IDO1AGXTAPLNRFFAR1 | |
| SCHEMBL17305607 | 0.77 | MEN1 (0.37) | TBXAS1IDO1AGXTAPLNRFFAR1 | |
| SCHEMBL12047343 | 0.75 | HDAC2 (0.36) | TBXAS1IDO1AGXT | |
| SCHEMBL29770026 | 0.74 | CNR1 (0.40) | TBXAS1IDO1AGXT | |
| SCHEMBL14587571 | 0.73 | TBXAS1 (0.45) | TBXAS1 | |
| SCHEMBL15172744 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827257-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-11-28 | — | — | US | disclosed |
| US-9750759-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-09-05 | — | — | US | disclosed |
| EP-2597091-B1 | Antitumoral Compounds | PHARMA MAR SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-9187445-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2015-11-17 | — | — | US | disclosed |
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| US-8501968-B2 | Antitumoral dihydropyran-2-one compounds | PHARMAMAR, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| EP-2597091-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2013-05-29 | — | — | EP | disclosed |
| US-8324406-B2 | Antitumoral dihydropyran-2-one compounds | PHARMA MAR, S.A. (ES) | 2012-12-04 | — | — | US | disclosed |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | MARTIN LOPEZ MA JESUS (ES) | 2012-07-26 | — | — | US | disclosed |
| US-20120041063-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20110034549-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2011-02-10 | — | — | US | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | TP53, CCNY, RB1 | TBXAS1 2147/4885IDO1 1187/4885AGXT 274/4885 |
| US-20120041063-A2 | ANTITUMORAL COMPOUNDS | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | TBXAS1 2556/4885IDO1 2335/4885AGXT 774/4885 |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | TBXAS1 2705/4885IDO1 3750/4885AGXT 3365/4885 |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | TP53, CCNY, RB1 | TBXAS1 2147/4885IDO1 1187/4885AGXT 274/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | TBXAS1 2705/4885IDO1 3750/4885AGXT 3365/4885 |
| US-20100280108-A1 | Antitumoral Compounds | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | TBXAS1 2556/4885IDO1 2335/4885AGXT 774/4885 |
| US-20120190870-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | TBXAS1 2705/4885IDO1 3750/4885AGXT 3365/4885 |
| US-20110034549-A1 | Antitumoral Compounds | CCNY, RB1, TPD52L2 | TBXAS1 1860/4885IDO1 1331/4885AGXT 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.